Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer

NCT00762034 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00762034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00762034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2008
Completion date
December 31, 2014
Enrollment
939 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer